Mérieux Equity Partners

DeepUll is a biotechnology company dedicated to developing an innovative diagnostic system aimed at the early detection of sepsis. The company focuses on rapidly identifying pathogens and providing antibiogram results within hours. Utilizing artificial intelligence, DeepUll's system not only detects the causative infectious agents but also assesses the patient's immunological and functional status, allowing for predictive insights into the potential onset and progression of sepsis. This capability enables healthcare professionals to deliver timely clinical responses, even before symptoms manifest, ultimately improving patient outcomes and reducing the unnecessary use of antimicrobials.

Ceva Santé Animale S.A. specializes in the research, development, production, and marketing of veterinary pharmaceuticals and vaccines for both companion and farm animals. The company provides a diverse range of products, including treatments for behavior, cardiology, nephrology, dermatology, locomotion, parasitology, and reproduction management for companion animals. For farm animals, Ceva offers anti-infective products, vaccines, and reproductive management solutions for cattle, sheep, goats, swine, and poultry. Additionally, the company has developed tools such as the Ceva Lung Program, a mobile application that helps manage lung health in livestock. Established in 1988 and headquartered in Libourne, France, Ceva operates pharmaceutical and research facilities in various countries, including Canada, Brazil, Italy, Hungary, the United States, Japan, Mexico, China, and Canada. The company is actively involved in global welfare initiatives, collaborating with local organizations to enhance animal health and welfare.

Curea Medical specializes in manufacturing advanced wound care dressings. Their products focus on efficient exudate management and superior absorption, utilizing proprietary SuperCore technology. They offer a range of solutions, including wound dressings for skin protection and hygiene, sensitive skin management, and malodorous wounds. Additionally, they provide plast silicone tape and seamless tubular bandages.

CorFlow Therapeutics is a medtech startup focused on developing innovative technologies for the diagnosis and treatment of microvascular obstructions in patients experiencing heart attacks. The company has created a controlled flow infusion system that utilizes a proprietary concept to measure microvascular resistance, allowing interventional cardiologists to assess the severity of microvascular obstruction. By comparing these measurements with post-procedure contrast-enhanced magnetic resonance imaging, CorFlow's technology aims to improve the diagnosis and treatment of microvascular obstruction, potentially reducing both short- and long-term complications for severe heart attack patients. Through its advancements, CorFlow is committed to addressing significant unmet medical needs in cardiology.

Prothea Technologies is a private medical technology company focused on innovating solutions for lung cancer diagnosis and treatment. Its primary offering is a specialized medical device that integrates a Microendoscope with an advanced image processing system. This technology enhances visualization during procedures, allowing for in situ analysis of lesion structures at a molecular level. By streamlining the biopsy and therapy process into a single hospital visit, Prothea Technologies aims to improve medical outcomes for lung cancer patients, facilitating more efficient and effective care.

Innosyn uses flow chemistry, bio- and chemocatalysis to produce chemicals product or enzymes along with optimization of plant processes.

Labquality is a provider of quality assurance solutions for medical laboratories and point of care testing, focusing on enhancing patient safety through independent quality assessments. The company offers a range of services including certification, regulatory consulting, traceable quality controls, and calibrator reference materials. Additionally, Labquality provides training services to assist clients in navigating industry regulations, managing quality, and obtaining marketing authorizations. By delivering these essential services, Labquality supports healthcare professionals in maintaining high standards of quality and compliance within the medical technology sector.

Amyl Therapeutics is a preclinical stage biotechnology company focused on developing innovative therapeutics for the treatment of amyloidosis and related neurodegenerative diseases. The company employs a novel mechanism to target and bind to the amyloid folds of toxic protein aggregates, including those associated with conditions like systemic amyloidosis and neurodegenerative disorders such as Alzheimer's and Parkinson's diseases. By addressing misfolded proteins, including antibody light chain and transthyretin aggregates, as well as amyloid-β, Tau, and α-synuclein aggregates, Amyl Therapeutics aims to provide effective treatments that can prevent the accumulation of these harmful proteins in both peripheral organs and the brain. This approach offers the potential for significant advancements in managing diseases related to protein misfolding.

Broken String Biosciences is focused on developing a novel sequencing platform aimed at assessing genome stability to enhance the safety and efficacy of cell and gene therapies. By integrating advanced sequencing techniques with bioinformatics analysis and artificial intelligence, the company provides healthcare professionals with a comprehensive, data-driven approach to medicine. This innovative platform is designed to facilitate the development of the next generation of therapies, ensuring they are safer by design and capable of addressing various medical challenges. Through its efforts, Broken String Biosciences aims to unlock new possibilities in the realm of advanced therapeutic solutions.

TISSIUM is a medical device company headquartered in Paris, France, focused on the development and commercialization of innovative biodegradable sealants and adhesives for surgical wound closure, particularly in minimally invasive procedures. The company's products are designed to be non-toxic, provide strong adhesion to tissues, and enable rapid wound closure in the body's dynamic environments. TISSIUM leverages advanced research and intellectual property from renowned laboratories, including those of Robert Langer at MIT and Jeff Karp at Brigham and Women’s Hospital. Its technology platform includes a proprietary family of fully biosynthetic, biomorphic, and programmable polymers, which are tailored for tissue reconstruction across various clinical applications. Founded in 2013, TISSIUM is supported by leading healthcare investors and aims to address unmet clinical needs through its groundbreaking approach to wound management.

Mablink Bioscience is a biotechnology company focused on developing a new class of cancer therapies known as Antibody Drug Conjugates (ADCs). The company specializes in designing homogeneous, plasma-stable ADCs that maintain their original pharmacological properties while achieving a high drug-to-antibody ratio (DAR). This innovative approach aims to provide healthcare professionals with enhanced treatment options for cancer patients, ultimately improving therapeutic outcomes.

AstriVax is a biotechnology company focused on developing innovative vaccines that address significant challenges in the field of vaccinology. The company aims to achieve initial clinical validation of its platform technology, which is designed to create a diverse pipeline of vaccines. AstriVax's vaccine candidates are engineered to minimize cold chain requirements, making them more accessible and easier to distribute. Additionally, these vaccines are intended to provide broad and long-lasting protection against a variety of viruses and pathogens, thereby enhancing treatment options within the healthcare sector.

Cairdac is a medical technology startup specializing in the development of innovative cardiac pacing systems. The company's flagship product is ALPS™, a self-sustaining, leadless pacemaker powered by a proprietary piezoelectric energy harvester that converts heart motion into electrical energy. This unique power source enables ALPS™ to have an extended lifespan of over 15 years, reducing the need for battery replacements and improving patient outcomes. Cairdac's mission is to provide cost-effective, disruptive solutions to traditional pacing systems, enhancing patients' quality of life and addressing growing healthcare needs.

SeqOne S.A.S. is a company based in Montpellier, France, that specializes in developing genomic data analysis software for the healthcare industry. Founded in 2017, SeqOne's platform offers end-to-end management of next-generation sequencing (NGS) and bioinformatics data, providing advanced tools for analyzing complex genomic information. The software is designed to deliver medically actionable results across various areas, including oncology, hematological diseases, rare diseases, genetic screening, and hereditary conditions. By addressing the challenges associated with analyzing rich genomic data, SeqOne aims to enhance the accessibility and effectiveness of genomic medicine, thereby facilitating improved treatment options for patients. The company serves both private and public healthcare sectors, contributing to the ongoing transformation of healthcare through the integration of genomic insights.

Dental Monitoring, founded in 2014 by CEO Philippe Salah, is a leader in remote dental monitoring solutions, driven by advanced artificial intelligence. The company has grown significantly, expanding its international presence with over 400 employees across Europe, the USA, Australia, Hong Kong, and Singapore. Its innovative platform is designed to empower dental professionals by creating automated workflows and patient communication protocols. Utilizing patented hardware, Dental Monitoring enables patients to submit high-quality intraoral images at their convenience, allowing for precise analysis of treatment compatibility. This technology enhances practice efficiency and enables effective virtual monitoring of various dental cases, ultimately improving patient care and outcomes.

Amyl Therapeutics is a preclinical stage biotechnology company focused on developing innovative therapeutics for the treatment of amyloidosis and related neurodegenerative diseases. The company employs a novel mechanism to target and bind to the amyloid folds of toxic protein aggregates, including those associated with conditions like systemic amyloidosis and neurodegenerative disorders such as Alzheimer's and Parkinson's diseases. By addressing misfolded proteins, including antibody light chain and transthyretin aggregates, as well as amyloid-β, Tau, and α-synuclein aggregates, Amyl Therapeutics aims to provide effective treatments that can prevent the accumulation of these harmful proteins in both peripheral organs and the brain. This approach offers the potential for significant advancements in managing diseases related to protein misfolding.

Swixx Biopharma is a specialized company that provides comprehensive representation for biopharma, over-the-counter (OTC), and medical device firms in Central and Eastern Europe (CEE). Founded in 2014 and based in Baar, Switzerland, Swixx Biopharma operates fully-owned affiliates across various CEE countries, including Albania, Bulgaria, Poland, and Romania, among others. The company aims to fill the gap left by multinational corporations that choose not to enter or exit specific markets or therapeutic areas. With a focus on rare diseases, oncology-hematology, specialty treatments, and self-medication, Swixx Biopharma leverages its research expertise to deliver effective health solutions tailored to the needs of the region.

AcuSurgical is a startup focused on advancing vitreo-retinal surgery through innovative technology. The company is developing a robotic surgical assistant specifically designed for retinal microsurgery, which aims to enhance the precision of eye operations. By providing surgeons with improved tools, AcuSurgical's device addresses common challenges faced in the treatment of retinal diseases, such as age-related macular degeneration. The technology helps filter hand tremors and enhances visualization during procedures, ultimately enabling better patient outcomes in the field of ophthalmic surgery.

Plantex is a manufacturer specializing in plant extracts for various applications, including nutraceuticals, food, animal nutrition, and cosmetics. The company produces a range of standardized products such as dry, liquid, soft, glycolic, and hydro-glycerinated extracts derived from natural raw materials. By leveraging its expertise in plant knowledge and production, Plantex aims to fulfill client requirements for authenticity, efficiency, and innovation in formulations, solubilization, and compression.

keepMED Ltd. is a medical technology company based in Rishon Le Zion, Israel, dedicated to developing innovative solutions for the treatment of Obstructive Sleep Apnea (OSA). Founded in 2012 and formerly known as Ninox Medical Ltd., the company has created keePAP, a wearable device designed to address the challenges associated with OSA. This device features a lightweight and unobtrusive nasal interface paired with a compact, battery-operated control unit, allowing for effective management of upper airway obstruction during sleep. Through its focus on disruptive technology, keepMED aims to improve the quality of life for individuals affected by this common sleep disorder.

TARA Biosystems, Inc. is a biotechnology company that specializes in developing organ-on-a-chip technology for evaluating new therapies and drug compounds, particularly in the field of cardiac medicine. Founded in 2014 and based in the United States, the company produces predictive in vitro human cardiac tissue models derived from human stem cells. These models are matured to physiologically relevant adult-like levels, allowing for accurate measurement of cardiac functionality, including contractile force. TARA Biosystems focuses on enhancing drug discovery and safety assessment processes by providing high-fidelity solutions that enable faster and safer development of new medicines. By harnessing human biology and data, the company aims to transform cardiac drug discovery and improve patient health outcomes.

Ceva Santé Animale S.A. specializes in the research, development, production, and marketing of veterinary pharmaceuticals and vaccines for both companion and farm animals. The company provides a diverse range of products, including treatments for behavior, cardiology, nephrology, dermatology, locomotion, parasitology, and reproduction management for companion animals. For farm animals, Ceva offers anti-infective products, vaccines, and reproductive management solutions for cattle, sheep, goats, swine, and poultry. Additionally, the company has developed tools such as the Ceva Lung Program, a mobile application that helps manage lung health in livestock. Established in 1988 and headquartered in Libourne, France, Ceva operates pharmaceutical and research facilities in various countries, including Canada, Brazil, Italy, Hungary, the United States, Japan, Mexico, China, and Canada. The company is actively involved in global welfare initiatives, collaborating with local organizations to enhance animal health and welfare.

Addmedica is a French company focused on the development and manufacturing of personalized medical products and specialty pharmaceuticals designed for patients with rare and serious medical conditions. The company addresses significant unmet medical needs in niche markets, particularly in the treatment of diseases such as sickle cell disease. By offering innovative solutions that can be used alongside or as alternatives to traditional drugs, Addmedica provides high medical value to healthcare professionals, patients, and managed care organizations. Its expertise and dedicated organizational structure enable Addmedica to effectively target and procure specialized medical products globally, ensuring that the unique needs of patients are met.

Mabtech AB is a biotech company based in Stockholm, Sweden, specializing in the development and manufacture of monoclonal antibodies and diagnostic kits. Founded in 1986, the company offers a range of products for enzyme-linked immuno sorbent assay (ELISA), enzyme-linked immunospot assay (ELISpot), and FluoroSpot methods, facilitating the detection of cytokines and other immunological molecules. Mabtech's product portfolio includes monoclonal antibodies for various applications, as well as specialized kits for ELISA, ELISpot, and FluoroSpot, which allow for the simultaneous detection of multiple analytes. The company serves a diverse clientele, providing tools for research involving human and animal samples across various species. Mabtech sells its products online and has established locations in the United States, Australia, Germany, and France, operating as a subsidiary of Mabtech Group AB.

Amphivena Therapeutics, Inc. is a clinical-stage immuno-oncology company based in South San Francisco, California, dedicated to developing bifunctional antibody therapies for hematologic malignancies. Founded in 2012, the company focuses on eradicating blood cancers by leveraging the patient's immune system to target and destroy tumor cells and their precursors. Amphivena's proprietary ReSTORE platform creates dual-action biologics that not only relieve immune suppression but also activate T cell effector functions in cancer patients. This platform is designed with features such as avid binding, target selectivity, and enhanced safety, and can be further engineered to include solid tumor targeting capabilities. By offering differentiated cancer immunotherapies, Amphivena Therapeutics aims to provide new treatment options for patients who are underserved by existing immunotherapies.

Keranova S.A., founded in 2015 and based in Saint Etienne, France, with an additional office in Vénissieux, specializes in the design and development of innovative surgical equipment for ophthalmologic procedures, specifically targeting the anterior segment of the eye. The company focuses on creating advanced surgical instruments that utilize a unique patented technology to enhance the efficiency and accuracy of ophthalmic surgeries. By introducing automation into these procedures, Keranova aims to reduce the reliance on manual techniques, offering equipment equipped with vision systems, intelligent software, and precise robotic movements. This approach represents a significant advancement in ophthalmic surgery, allowing for more reproducible outcomes and improved patient care.

Doc Generici s.r.l., established in Milan, Italy, specializes in producing and distributing generic medicines within Italy. Its extensive product portfolio spans various therapeutic areas, including anti-infectives, cardiovascular, dermatological, gastrointestinal, neurological, respiratory, and others. Additionally, the company offers nutritional supplements and medical devices. Doc Generici is a subsidiary of Diocle S.p.A., founded in 1996 following the approval of equivalent medicine use laws. It laid the groundwork for entering the generic market between 1996 and 2001, when pharmacists became obligated to provide the lowest-priced equivalent medicines upon prescription. In 2013, Doc Generici was acquired by Charterhouse Capital Partners LLP, maintaining its independence and commitment to affordable, quality generic pharmaceuticals.

Inscripta, Inc. is a gene editing technology company based in Boulder, Colorado, with additional offices in Pleasanton and San Diego, California. Founded in 2015, Inscripta focuses on developing CRISPR enzymes, specifically MADzymes, for precision gene editing. The company has created a benchtop platform for scalable digital genome engineering, which includes an instrument, consumables, software, and assays that facilitate a fully automated workflow. This platform allows for massively parallel and trackable editing of single cells, significantly enhancing the scale and efficiency of gene editing research. By making its MAD7 CRISPR nuclease freely available for research and development, Inscripta aims to remove existing technical and licensing barriers, thereby empowering scientists and fostering a new era of biological discovery.

Omnipharm, is a supplier of natural ingredients made in France

Inscripta, Inc. is a gene editing technology company based in Boulder, Colorado, with additional offices in Pleasanton and San Diego, California. Founded in 2015, Inscripta focuses on developing CRISPR enzymes, specifically MADzymes, for precision gene editing. The company has created a benchtop platform for scalable digital genome engineering, which includes an instrument, consumables, software, and assays that facilitate a fully automated workflow. This platform allows for massively parallel and trackable editing of single cells, significantly enhancing the scale and efficiency of gene editing research. By making its MAD7 CRISPR nuclease freely available for research and development, Inscripta aims to remove existing technical and licensing barriers, thereby empowering scientists and fostering a new era of biological discovery.

Biobest N.V. is a company that develops and supplies natural crop care systems, focusing on bumblebee pollination and sustainable crop management. It offers a range of products, including biological pollination solutions like bumblebees, biological control products such as beneficial insects, mites, nematodes, and biopesticides. Additionally, Biobest provides monitoring and scouting tools, including sticky traps, pheromone traps, and lures, designed to assist growers in managing pests. The company also supplies various supporting products, including food supplements for predatory bugs, nutritional supplements based on pollen, foliar fertilizers, and tools for pest detection. Founded in 1987 and based in Westerlo, Belgium, Biobest operates through distributors both domestically and internationally, supported by a network of subsidiaries and production sites. The company is dedicated to providing technical advisory and support services to enhance crop care practices.

Xeris Biopharma Holdings is a specialty pharmaceutical company focused on developing and commercializing innovative therapies for patients in endocrinology, neurology, and gastroenterology. The company utilizes its proprietary formulation technologies, XeriSol and XeriJect, to create ready-to-use, liquid-stable injectables that facilitate subcutaneous and intramuscular delivery of various therapeutic agents. Xeris offers three commercially available products: Gvoke, a liquid glucagon for severe hypoglycemia; Keveyis, the first FDA-approved treatment for primary periodic paralysis; and Recorlev, approved for endogenous hypercortisolemia in adults with Cushing's Syndrome. Xeris Biopharma's formulation platforms aim to improve patient and caregiver ease of use by eliminating reconstitution, ensuring long-term stability at room temperature, and reducing injection volume, thereby enhancing healthcare delivery and potentially lowering costs for the healthcare system. The company is also advancing a pipeline of development programs to expand its product offerings.

Inscripta, Inc. is a gene editing technology company based in Boulder, Colorado, with additional offices in Pleasanton and San Diego, California. Founded in 2015, Inscripta focuses on developing CRISPR enzymes, specifically MADzymes, for precision gene editing. The company has created a benchtop platform for scalable digital genome engineering, which includes an instrument, consumables, software, and assays that facilitate a fully automated workflow. This platform allows for massively parallel and trackable editing of single cells, significantly enhancing the scale and efficiency of gene editing research. By making its MAD7 CRISPR nuclease freely available for research and development, Inscripta aims to remove existing technical and licensing barriers, thereby empowering scientists and fostering a new era of biological discovery.

Stiplastics S.A.S. specializes in the design, development, and manufacturing of medical devices for the healthcare sector, both in France and internationally. Established in 1985 and headquartered in Beauvoir-en-Royans, the company offers a diverse range of products, including distributor pumps, tamper-proof containers, caps, closures, cosmetic spatulas, nozzles, droppers, measuring scoops, and various packaging solutions. Additionally, it provides pharmaceutical packaging products, carrying cases for biological samples, and pillboxes. Stiplastics S.A.S. distributes its offerings through a comprehensive catalog, catering to the needs of the healthcare industry.

Laboratoires Ineldea, founded in 2003 and based in Carros, France, specializes in the formulation, development, manufacturing, and marketing of a diverse range of health-related products. These include nutritional supplements, food supplements, health foods, organic cosmetics, and healthcare products, as well as nutraceutical solutions. With a product portfolio exceeding 400 references, the company emphasizes innovation, launching multiple new products each year. Laboratoires Ineldea leverages over 20 years of expertise in natural products to ensure high-quality offerings that have earned the trust of healthcare professionals and consumers alike. The company markets its products through various channels, including pharmacies, drugstores, specialty stores, and health professionals, targeting individuals at all stages of life to support their health and well-being.

PhysioAssist, established in 2012, specializes in developing medical devices aimed at treating obstructive respiratory diseases. Their flagship product employs proprietary technology designed to alter the physical properties of mucus, facilitating its mobilization and removal. This innovation enables healthcare professionals to provide more effective treatment for patients suffering from conditions such as chronic bronchitis and cystic fibrosis, improving their overall quality of life. The company's solutions have been meticulously designed with patient comfort and daily care practicality in mind.

Xeris Biopharma Holdings is a specialty pharmaceutical company focused on developing and commercializing innovative therapies for patients in endocrinology, neurology, and gastroenterology. The company utilizes its proprietary formulation technologies, XeriSol and XeriJect, to create ready-to-use, liquid-stable injectables that facilitate subcutaneous and intramuscular delivery of various therapeutic agents. Xeris offers three commercially available products: Gvoke, a liquid glucagon for severe hypoglycemia; Keveyis, the first FDA-approved treatment for primary periodic paralysis; and Recorlev, approved for endogenous hypercortisolemia in adults with Cushing's Syndrome. Xeris Biopharma's formulation platforms aim to improve patient and caregiver ease of use by eliminating reconstitution, ensuring long-term stability at room temperature, and reducing injection volume, thereby enhancing healthcare delivery and potentially lowering costs for the healthcare system. The company is also advancing a pipeline of development programs to expand its product offerings.

Ivantis Inc. is a medical device company based in Irvine, California, focused on developing innovative treatments for primary open-angle glaucoma. Founded in 2007, the company has created a minimally invasive intracanalicular scaffold that helps alleviate high intraocular pressure by restoring the natural drainage pathway in Schlemm's canal. This device aims to provide a less invasive and more effective solution for the over 60 million individuals worldwide affected by this condition. In addition to its glaucoma treatments, Ivantis plans to expand its research and development efforts to address other challenging diseases within the field of ophthalmology. The company's products are utilized in clinical trials by ophthalmology specialists across the United States.

LNA Sante is a global health player with nearly 70 establishments in France and Belgium. Nursing homes (EHPAD and MRS), Follow-up care and rehabilitation (SSR), Home hospitalization structures (HAD), Health centers, Psychiatric clinic. Our mission is to improve the quality of life for people who are temporarily or permanently vulnerable, in a welcoming and caring environment, suitable for everyone and for all ages. Our commitment "To care and take care" of you or your loved ones daily, patients and residents who are welcomed in our structures in France or in Belgium. A mission and commitment shared by all our teams.

Seqens is a provider of pharmaceutical ingredients and specialty chemicals headquartered in Ecully, France. The company specializes in the synthesis of active pharmaceutical ingredients (APIs) including aspirin, paracetamol, salicylic acid, and para-aminophenol, along with a range of specialty chemicals such as soda ash, sodium bicarbonate, phenol, oxygenated solvents, and ferric chloride. Seqens serves various demanding industries, including healthcare, electronics, cosmetics, food, and household cleaning products. The company is known for its market responsiveness and ability to deliver customized solutions tailored to the specific needs of its customers.

Keranova S.A., founded in 2015 and based in Saint Etienne, France, with an additional office in Vénissieux, specializes in the design and development of innovative surgical equipment for ophthalmologic procedures, specifically targeting the anterior segment of the eye. The company focuses on creating advanced surgical instruments that utilize a unique patented technology to enhance the efficiency and accuracy of ophthalmic surgeries. By introducing automation into these procedures, Keranova aims to reduce the reliance on manual techniques, offering equipment equipped with vision systems, intelligent software, and precise robotic movements. This approach represents a significant advancement in ophthalmic surgery, allowing for more reproducible outcomes and improved patient care.

Novacap is a prominent manufacturer and distributor of essential chemicals used in everyday products. They offer a wide range of products including salicylic acid, aspirin, paracetamol, para-aminophenol, soda ash, sodium bicarbonate, phenol, oxygenated solvents, hydrochloric acid, and derivatives. Novacap serves various industries such as pharmaceutical & healthcare, food & feed, cosmetics & fragrances, home care, and environment. They are a key partner in the construction and automotive markets as well. With a strong presence in these markets, Novacap is a global leader in providing essential chemicals for a wide range of applications.

Twist Bioscience Corporation is a synthetic biology company that specializes in the manufacture and sale of synthetic DNA-based products. Founded in 2013 and headquartered in South San Francisco, California, the company utilizes a proprietary semiconductor-based DNA synthesis platform that writes DNA on silicon chips, allowing for the rapid and cost-effective production of high-quality synthetic DNA. Twist Bioscience's offerings include synthetic genes, tools for sample preparation, antibody libraries for drug discovery, and DNA as a medium for digital data storage. The company serves various sectors, including healthcare, agriculture, and industrial chemicals, supporting customers in their efforts to enhance lives and promote sustainability. Through its innovative platform, Twist Bioscience aims to overcome traditional inefficiencies in DNA synthesis, enabling researchers to accelerate their projects.

OriGene Technologies, Inc. is a biotechnology company based in Rockville, Maryland, specializing in the development, manufacturing, and sale of genome-wide research and diagnostic products. Established in 1995, OriGene offers a comprehensive array of tools for academic, diagnostic, pharmaceutical, and biotech applications. Its product portfolio includes cDNA clones, shRNA and siRNA reagents, CRISPR/Cas9 genome editing tools, proteins, antibodies, and anatomic pathology products. Additionally, the company provides services such as gene synthesis, custom cloning, and assay development, supporting a variety of research areas including cancer biomarker research and stem cell research. OriGene's extensive resources aim to facilitate gene-based research, enabling researchers to validate antibodies and develop new drugs. The company's products are distributed globally through various channels, including online platforms.

keepMED Ltd. is a medical technology company based in Rishon Le Zion, Israel, dedicated to developing innovative solutions for the treatment of Obstructive Sleep Apnea (OSA). Founded in 2012 and formerly known as Ninox Medical Ltd., the company has created keePAP, a wearable device designed to address the challenges associated with OSA. This device features a lightweight and unobtrusive nasal interface paired with a compact, battery-operated control unit, allowing for effective management of upper airway obstruction during sleep. Through its focus on disruptive technology, keepMED aims to improve the quality of life for individuals affected by this common sleep disorder.

Ceva Santé Animale S.A. specializes in the research, development, production, and marketing of veterinary pharmaceuticals and vaccines for both companion and farm animals. The company provides a diverse range of products, including treatments for behavior, cardiology, nephrology, dermatology, locomotion, parasitology, and reproduction management for companion animals. For farm animals, Ceva offers anti-infective products, vaccines, and reproductive management solutions for cattle, sheep, goats, swine, and poultry. Additionally, the company has developed tools such as the Ceva Lung Program, a mobile application that helps manage lung health in livestock. Established in 1988 and headquartered in Libourne, France, Ceva operates pharmaceutical and research facilities in various countries, including Canada, Brazil, Italy, Hungary, the United States, Japan, Mexico, China, and Canada. The company is actively involved in global welfare initiatives, collaborating with local organizations to enhance animal health and welfare.

ImaginAb, Inc. is a clinical stage biotechnology company specializing in immune oncology imaging and radiopharmaceutical therapy. Founded in 2007 and based in Inglewood, California, the company develops engineered antibody fragments, specifically minibodies, to provide diagnostic imaging solutions and insights into cancer immunotherapy. Its product line includes advanced imaging agents such as the CD8 ImmunoPET™ and PSMA PET, which target specific molecular markers in various cancers, including prostate and immune-oncology. These imaging agents are designed to enhance patient selection and monitor treatment progress, facilitating precision medicine. Currently, ImaginAb's lead candidate, 89Zr crefmirlimab berdoxam, is undergoing Phase II clinical trials and has been licensed by multiple pharmaceutical and biotech companies for use in their immunotherapy clinical trials.

Kalila Medical specializes in developing advanced catheter technologies focused on vascular and intracardiac access. Founded in 2010, the company offers a platform of specialized delivery and access catheters, with a primary product line that includes steerable sheaths designed for catheter-based atrial fibrillation ablation. These sheaths, compatible with various ablation catheters, enhance precision by providing superior torque and tip control during catheter delivery and lesion formation. Additionally, Kalila Medical's technologies are applicable across a range of endovascular procedures, including mitral valve repair, ASD/PFO closure, left atrial appendage closure, transseptal puncture, and LV lead placement. The company is part of a portfolio formed from Shifamed LLC, a Silicon Valley-based medical device incubator.

Proclara Biosciences, Inc. is a biotechnology company focused on developing innovative therapies for chronic neurodegenerative diseases, particularly amyloidoses, Alzheimer's disease, and Parkinson's disease. Established in 2006 and headquartered in Cambridge, Massachusetts, the company specializes in a protein disaggregation platform that targets and recognizes misfolded proteins associated with these conditions. Proclara's approach aims to create disease-modifying treatments that could significantly improve patient outcomes. The company was previously known as NeuroPhage Pharmaceuticals, Inc. before rebranding in September 2016. Through its research and development efforts, Proclara strives to address unmet medical needs in the field of neurodegeneration and related disorders.

Lavorel Medicare is a service provider focused on nursing care, offering support both at home and in specialized care units. The company operates a German subsidiary, Bonitas GmbH, which employs approximately 3,000 staff members dedicated to providing medical assistance to disabled patients with chronic illnesses or genetic conditions. Bonitas GmbH serves over 2,000 patients across Germany, operating through a network of 50 agencies to ensure comprehensive care and support.

HumanCharger is a company that specializes in developing innovative light therapy devices aimed at enhancing mental well-being and performance. Its flagship product utilizes a patented mechanism that delivers calibrated white light through the ear canals to stimulate photosensitive proteins in the brain. This pocket-sized device is designed for daily use, requiring only 12 minutes to help users increase energy levels, improve mood, and enhance mental alertness. Additionally, the HumanCharger device is effective in alleviating symptoms of seasonal affective disorder and mitigating the effects of jet lag, making it a versatile tool for consumers seeking to optimize their cognitive function and overall mental health.

Lavorel Medicare is a service provider focused on nursing care, offering support both at home and in specialized care units. The company operates a German subsidiary, Bonitas GmbH, which employs approximately 3,000 staff members dedicated to providing medical assistance to disabled patients with chronic illnesses or genetic conditions. Bonitas GmbH serves over 2,000 patients across Germany, operating through a network of 50 agencies to ensure comprehensive care and support.

Proclara Biosciences, Inc. is a biotechnology company focused on developing innovative therapies for chronic neurodegenerative diseases, particularly amyloidoses, Alzheimer's disease, and Parkinson's disease. Established in 2006 and headquartered in Cambridge, Massachusetts, the company specializes in a protein disaggregation platform that targets and recognizes misfolded proteins associated with these conditions. Proclara's approach aims to create disease-modifying treatments that could significantly improve patient outcomes. The company was previously known as NeuroPhage Pharmaceuticals, Inc. before rebranding in September 2016. Through its research and development efforts, Proclara strives to address unmet medical needs in the field of neurodegeneration and related disorders.

Biom'Up S.A. is a French company specializing in the development and commercialization of innovative hemostatic products and absorbable medical devices based on patented biopolymer and collagen technologies. Founded in 2005 and headquartered in Saint-Priest, France, Biom'Up designs and manufactures medical devices aimed at improving surgical outcomes across various specialties, including orthopedic, spinal, cardiac, general, and maxillofacial surgeries. Its flagship products, such as HEMOBLAST bellows and associated laparoscopic applicators, are clinically proven to enhance patient healing by facilitating guided regeneration of soft tissues and bone. The company markets its products primarily in Europe and the United States, contributing significantly to the field of biosurgery.

Advencis is a developer and manufacturer of lab instruments and medical devices.The company has developed Advencis Bio-System Incubator, a modular system of early detection which is fully automated for industrial microbiology (food and pharmaceutical industries) and clinical markets. The system provides highly sensitive detection of the microorganisms on agar plates and on filter-based devices. It also provides Advencis Bio-System Software which is a real time monitoring application.

Proclara Biosciences, Inc. is a biotechnology company focused on developing innovative therapies for chronic neurodegenerative diseases, particularly amyloidoses, Alzheimer's disease, and Parkinson's disease. Established in 2006 and headquartered in Cambridge, Massachusetts, the company specializes in a protein disaggregation platform that targets and recognizes misfolded proteins associated with these conditions. Proclara's approach aims to create disease-modifying treatments that could significantly improve patient outcomes. The company was previously known as NeuroPhage Pharmaceuticals, Inc. before rebranding in September 2016. Through its research and development efforts, Proclara strives to address unmet medical needs in the field of neurodegeneration and related disorders.

AMPLITUDE TECHNOLOGIES is the global expert in the science, design and manufacture of high performance laser systems for a variety of specialist applications. ln addition to systems used for fundamental physics research, the company is a leading authority in the medical research domain including radiography and cancer treatment projects. AMPLITUDE TECHNOLOGIES offers worldwide project management experience. Its comprehensive project management program provides industry-leading levels of customer support. From the first steps of the design concept, to laboratory installation, training and ongoing after-sales requirements, the Amplitude team is on-hand to provide the support the application demands. Over a decade' s experience in the Science, design and development, and support of state-of-the-art systems in the field means that every AMPLITUDE TECHNOLOGIES system is engineered to be extremely robust and reliable, offering unparalleled performance no matter what the application.

Proclara Biosciences, Inc. is a biotechnology company focused on developing innovative therapies for chronic neurodegenerative diseases, particularly amyloidoses, Alzheimer's disease, and Parkinson's disease. Established in 2006 and headquartered in Cambridge, Massachusetts, the company specializes in a protein disaggregation platform that targets and recognizes misfolded proteins associated with these conditions. Proclara's approach aims to create disease-modifying treatments that could significantly improve patient outcomes. The company was previously known as NeuroPhage Pharmaceuticals, Inc. before rebranding in September 2016. Through its research and development efforts, Proclara strives to address unmet medical needs in the field of neurodegeneration and related disorders.

QuantaLife, Inc. is a biotechnology startup focused on the development, manufacture, and marketing of innovative nucleic acid testing solutions for various markets, including life science research and clinical diagnostics. The company is pioneering a genetic analysis platform designed for medical diagnostic applications, offering advanced systems that deliver cost-effective, high-resolution capabilities. QuantaLife's proprietary technology significantly enhances the rapid detection and quantification of nucleic acids in complex samples using a flexible, automated instrument. This approach offers substantial performance improvements over existing platforms, enabling researchers to explore intricate genetic landscapes, identify new disease associations, and create enhanced molecular diagnostic tests. Currently, QuantaLife is in the early development stages, working towards transforming the field of genetic analysis.

SuperSonic Imagine SA is a medical technology company based in Aix-en-Provence, France, specializing in the development and manufacture of ultrasound imaging systems. Founded in 2005, the company is recognized for its Aixplorer system, which delivers high-definition, high-contrast imaging crucial for diagnosing and monitoring various conditions, including breast, prostate, and thyroid cancers, as well as liver diseases. SuperSonic Imagine also offers the ShearWave technology platform, which focuses on quantitative elastography for assessing tissue elasticity. The company operates primarily in France, the United States, and China, and distributes its products through a network of offices and partners across various countries, including Belgium, Germany, and the United Kingdom. As a subsidiary of Hologic Hub Ltd, SuperSonic Imagine continues to innovate in the field of medical imaging technology, enhancing the capabilities of healthcare practitioners.

SeqOne S.A.S. is a company based in Montpellier, France, that specializes in developing genomic data analysis software for the healthcare industry. Founded in 2017, SeqOne's platform offers end-to-end management of next-generation sequencing (NGS) and bioinformatics data, providing advanced tools for analyzing complex genomic information. The software is designed to deliver medically actionable results across various areas, including oncology, hematological diseases, rare diseases, genetic screening, and hereditary conditions. By addressing the challenges associated with analyzing rich genomic data, SeqOne aims to enhance the accessibility and effectiveness of genomic medicine, thereby facilitating improved treatment options for patients. The company serves both private and public healthcare sectors, contributing to the ongoing transformation of healthcare through the integration of genomic insights.